112 related articles for article (PubMed ID: 2924885)
1. Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment.
Petrucci MT; Avvisati G; Tribalto M; Cantonetti M; Giovangrossi P; Mandelli F
Eur J Haematol; 1989 Mar; 42(3):233-7. PubMed ID: 2924885
[TBL] [Abstract][Full Text] [Related]
2. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
[TBL] [Abstract][Full Text] [Related]
3. Single-dose intravenous melphalan in advanced multiple myeloma.
Bäck H; Lindblad R; Rödjer S; Westin J
Acta Haematol; 1990; 83(4):183-6. PubMed ID: 2115714
[TBL] [Abstract][Full Text] [Related]
4. Intravenous melphalan and dexamethasone followed by lymphoblastoid alpha interferon in higher risk multiple myeloma patients.
Petrucci MT; La Verde G; Ribersani M; Avvisati G; Mandelli F
Leuk Lymphoma; 2000 Sep; 39(1-2):131-8. PubMed ID: 10975391
[TBL] [Abstract][Full Text] [Related]
5. Repeat administration of high dose melphalan in relapsed myeloma.
Mansi JL; Cunningham D; Viner C; Ellis E; Meldrum M; Milan S; Gore M
Br J Cancer; 1993 Nov; 68(5):983-7. PubMed ID: 8217614
[TBL] [Abstract][Full Text] [Related]
6. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
[TBL] [Abstract][Full Text] [Related]
8. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
[TBL] [Abstract][Full Text] [Related]
9. Short course intermediate dose intravenous melphalan therapy in myeloma--relation to early emergence of drug resistance (phase II study).
Sviland L; Leggat H; Harris AL; Bird G; Proctor SJ
Acta Haematol; 1987; 78(4):233-8. PubMed ID: 3122488
[TBL] [Abstract][Full Text] [Related]
10. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma treated with high dose intravenous melphalan.
Selby PJ; McElwain TJ; Nandi AC; Perren TJ; Powles RL; Tillyer CR; Osborne RJ; Slevin ML; Malpas JS
Br J Haematol; 1987 May; 66(1):55-62. PubMed ID: 3593657
[TBL] [Abstract][Full Text] [Related]
13. The use of intravenous intermediate dose melphalan and dexamethasone as induction treatment in the management of de novo multiple myeloma.
Schey SA; Kazmi M; Ireland R; Lakhani A
Eur J Haematol; 1998 Nov; 61(5):306-10. PubMed ID: 9855245
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
[TBL] [Abstract][Full Text] [Related]
16. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL
Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035
[TBL] [Abstract][Full Text] [Related]
17. Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients.
Palumbo A; Pileri A; Triolo S; Omedè P; Bruno B; Ciravegna G; Galliano M; Frieri R; Boccadoro M
Bone Marrow Transplant; 1997 Jan; 19(1):23-9. PubMed ID: 9012927
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
19. Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.
Ahre A; Björkholm M; Mellstedt H; Holm G; Brenning G; Engstedt L; Gahrton G; Hällen J; Johansson B; Johansson SG; Karnström L; Killander A; Lerner R; Lockner D; Lönnqvist B; Simonsson B; Stalfelt AM; Ternstedt B; Wadman B
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):499-506. PubMed ID: 6345174
[TBL] [Abstract][Full Text] [Related]
20. High-dose melphalan for multiple myeloma: long-term follow-up data.
Cunningham D; Paz-Ares L; Gore ME; Malpas J; Hickish T; Nicolson M; Meldrum M; Viner C; Milan S; Selby PJ
J Clin Oncol; 1994 Apr; 12(4):764-8. PubMed ID: 8151320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
